Coming soon | Research Report
The Animal Health Industry has gone through a period of unprecedented disruption and economic uncertainty due to the coronavirus pandemic.
As part of our continued commitment to the animal health industry Kisaco Research, founders of the Animal Health Investment global event series, will be conducting a indepth report to understand the full impact of the outbreak, across all players in the ecosystem.
The report will be a summation of industry surveys, data collection, KOL discussions, and interviews with market leaders and emerging companies, focused on the animal
health industry in the world of the COVID-19 epidemic.
During this unprecedented time, our goal is to understand the industry’s response, examine new scenarios, uncover accelerated periods of growth, and positive outcomes for animal health going forward.
Download the executive summary to register your interest and be the first to receive this exlcusive report which is due to be released mid-July 2020.
Download now
Why Attend
The Covid-19 pandemic is creating unprecedented disruption for the animal health industry with far reaching effects yet to be measured. In this uncertain time, there is a now a real need for greater collaboration and communication across the sector and among emerging businesses, large corporate entities, government agencies, NGOs, and investors.
At Kisaco Research we're committed to giving the animal health community a platform where we can come together, continue to create vital strategic connections and drive deal-making via virtual partnering meetings. We appreciate that this will be a new experience for many of you but operating virtually is now the new business norm and we look forward to working with you to make this a truly effective experience.
Join us virtually June 23rd -25th and access:
- 3 days of advanced, pre-scheduled, virtual networking using 1-2-1 video chat
- Highly relevant and informative content sessions, panel discussions and presentations
- An international business audience specific to animal health and nutrition
- The opportunity to engage with the most exciting emerging business and biotech in animal health
Speakers
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/huron_sebastien_portrait.jpg?itok=1EkqAONN&c=243909af74d69de6a0d323ca6f165991)
Sébastien Huron
Sébastien Huron, 46, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division. After rejoining the Virbac group in 2006 as the general manager of the Spanish subsidiary, he then became the director of the European region in 2008, and then head of Global Business Operations in 2013. He has been part of the Virbac executive board since December 2012.
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/georgia_wraight.png?itok=1BlPjc3T&c=14a9f36fdf4b385f4d0fb883c88b99f7)
Georgia Wraight
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/koffman_paul.jpg?itok=ctR-5O83&c=c88f42b15d2ec1b51814307aecff1671)
Paul Koffman
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/david_prien.png?itok=N550Al4h&c=72c817aa55a80aed636e1172e4659a16)
David Prien
David founded FirstVet in 2016 and has previously run several pet-related startups in the Nordics, taking them from early stages to exits. Graduated from SSE with a double degree in Business & Retail Management.
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/img_6521.jpg?itok=yoz5iAIL&c=4a1ae71432756eadbad15bced934342f)
Mark Boddy
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/victoria_johnson.jpg?itok=AwOMCllm&c=fe28d221c252701b88f983d43c5dc419)
Victoria Johnson
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/roy_stein_0.jpg?itok=XrKBQBQ3&c=2c0aba5e13b92ff857b3388b8892c601)
Roy Stein
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/anton_xavier_headshot.png?itok=oneIZpTC&c=22f9e5bb70fef30ec4ec81b9cef5e3ee)
Anton Xavier
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/ricky_ghoshal.png?itok=sxXmM4Yn&c=6e8f34dac7f8d0af2abe41d677f279b9)
Ricky Ghoshal
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/chris_belnap.jpg?itok=tM7ueq9b&c=703aac3191616b7d92a09c16887afb72)
Chris Belnap
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/rob_readnour.jpg?itok=8blxl4dy&c=6fdfa17ea68ef97b05d8dae0ebc16392)
Rob Readnour
Dr. Readnour currently serves on or has visitation rights to the following companies: AgTech Accelerator, a unique startup accelerator focused on discovering and developing emerging agricultural technology companies, Skyline Vet Pharma, a company that is developing veterinary pharmaceuticals using proven delivery technologies to reformulate drugs with established animal health markets, and Boragen, a company that is developing small molecule approaches focused on leveraging the unique chemical properties of boron chemistry, both in crop protection and animal health.
Prior to joining MGP, Dr. Readnour worked at Elanco Animal Health for 27 years. During his Elanco tenure, he held several senior management positions in which he was responsible for developing and executing Elanco’s Research and Development strategies for entering several new business areas (companion animal pharmaceuticals, vaccines and enzymes). In 2017, these new business areas accounted for nearly 50% of Elanco’s $3.0 billion in sales. Dr. Readnour played an important role in Elanco’s acquisition and integration of Novartis Animal Health, Lohmann Animal Health, ChemGen and Janssen Animal Health. Within Elanco, Dr. Readnour led several initiatives to transform Research and Development through the piloting of new approaches to developing animal health products. He developed and led Elanco’s new technology scouting, acquisition and due diligence efforts. He pioneered a lean product development model which allowed Elanco to enter new areas of business without significant capital investment. He led initial efforts for Elanco to invest in early stage companies and partner with external funding sources to develop products with minimal initial investment from Elanco. Dr. Readnour served as a member of the Food and Agriculture Section of Bio International Board and as an External Advisory Board member for University of Illinois Animal Science Department.
Prior to entering management in Elanco, Dr. Readnour was an internationally recognized expert on animal health product development, analytical chemistry, human food safety and drug residues with 11 publications and 14 external presentations. Throughout his career, Dr. Readnour was responsible for the development and commercialization of 10 animal health products. Dr. Readnour received his PhD in Analytical Chemistry from University of Illinois in 1990.
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/michael_boddington.png?itok=Nzjm7oLM&c=d12f66ff0b96245f7a19958dcd7e267e)
Mr. Michael Boddington
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/michael_helmstetter_2018_preferred.jpeg?itok=wX_3K80e&c=51e67be9674c37634192e15f033eb69f)
Michael Helmstetter
Dr. Michael Helmstetter is Co-Founder, President, and Chief Executive Officer of TechAccel LLC (Technology Acceleration Partners).
TechAccel is a technology and venture development company in the agriculture and animal health sectors. The company invests in or acquires new technology and funds science advancement programs with research university partners to assist in commercialization.
Michael also serves as Managing Partner of Covenant Animal Health Partners, a TechAccel subsidiary that focuses on development of “revenue-ready” animal health products for both companion and farm animals.
Before founding TechAccel, Michael served as the fifth President and Chief Executive Officer of MRIGlobal – one of the nation's most prominent research institutions. In his 14 years with MRIGlobal (formerly Midwest Research Institute), he led its growth from 2 to 17 national and international locations.
Michael has more than 30 years of experience working with the private sector and government agencies, including laboratory management positions at Applied Marine Research Laboratory in Norfolk, Va., and program management for the Harbor Branch Oceanographic Institution in Fort Pierce, Fla. He was President and Chairman of startup Brevard Teaching and Research Laboratories, a post he held until the company was acquired by MRIGlobal.
Michael received a Ph.D. in Chemical Toxicology/Oceanography from Old Dominion University and a B.S. in Biology from Allegheny College. He has been a panelist, keynote speaker, lecturer, reviewer to several journals, and is the author of numerous publications, articles, book chapters, and technical reports.
He has served on several boards, including Labconco Corp. Board of Directors and University of Missouri-Kansas City Board of Trustees, as well as numerous civic organizations. He is a contributing opinion writer for Forbes.com.
Michael lives in suburban Kansas City.
Email: [email protected]
LinkedIn www.linkedin.com/in/michaelhelmstetter/
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/psp_spencer_swayze.jpg?itok=0KbftR4N&c=4fdf6e079795ebeb94c4c3ff2509f4b8)
Spencer Swayze
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/capture_25.png?itok=9eDn4TfP&c=09689f4f8b40be504f23a79066689752)
Mr. Brian Axe
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/cynthia_cole.png?itok=VXSihC0x&c=4f1227500023880e22ca899eafaab16e)
Cindy Cole
Dr. Cindy Cole is a Technical Partner at Digitalis Ventures and an Associate Clinical Professor at the University of Florida. Prior to joining Digitalis she was in the animal health industry for many years holding senior leadership and R&D roles at Mars Petcare, Novartis Animal Health, IDEXX, and Piedmont Pharmaceuticals. Dr. Cole completed her DVM and PhD at the University of Florida and was on the faculty of the University of California, Davis and UF.
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/joost.jpg?itok=3wzQjdnR&c=1469a91dfe921bb4e875663f09d80bd6)
Joost Matthijssen
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/sarai_kemp.png?itok=Xsw6N4bF&c=5ea41234f2ded29a4655eb85ea460845)
Sarai Kemp
As VP Business Development for Trendlines Agrifood (Israel) since 2012 and VP Deal Flow for the Trendlines Agrifood Fund (Singapore), Sarai Kemp is responsible for sourcing start-ups, evaluating opportunities, negotiating, and closing investments and working with portfolio companies post-investment. Sarai is a board member on Hargol FoodTech, AgroScout, FruitSpec and AlgaHealth.
Sarai brings more than 20 years’ experience in agricultural, consumer goods, and high-tech industries, including in sales, marketing, and business development for international companies such as Afimilk and Keter Plastic. She has worked intensively with companies in East Asia.
Sarai received an MBA from Haifa University and a B.A. from Tel Aviv University.
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/laetitia-gerbe-188x188.jpg?itok=6xGUHzHv&c=4084e524230a7a096445571606c7fca9)
Laëtitia Gerbe
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/joyparrdrach_headshot.jpg?itok=HuYI3vXL&c=ad30d33071b3f5f6dbff6c6ad3dc1bb6)
Joy Parr Drach
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/daniella_dos_santos_photo.jpg?itok=h-5lzZYm&c=baff30799a1b2629440e12f33a560118)
Daniella Dos Santos
Daniella obtained a BSc (hons) in Molecular Genetics from Kings College London in 2007, before going to study veterinary medicine at the RVC, qualifying in 2012. Since then she has been in first opinion small animal and exotic animal practice and is currently working towards her CertAVP zoological medicine. She became a member of the BVA Ethics and Welfare Advisory Panel in 2015, and became Chair in 2017. She also became a Trustee of the Animal Welfare Foundation in 2016.
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/maarteen.jpg?itok=c4l_-k-c&c=6dba7b88948980fbbbcf03bfaa1af0ab)
Maarten Goossens
Maarten is a Co-founder and Principal at Anterra Capital. He began his investing career as an Analyst within the Rabo Ventures team in 2009 and was primarily responsible for deal sourcing and execution, and portfolio management.
Prior to joining Rabo Ventures, Maarten was an Analyst in the Rabobank-Rothschild M&A joint venture in London, where he focused on transactions in Food & Agriculture.
Maarten holds a Masters of Business Administration from the Free University of Amsterdam, and has studied at the London School of Economics.
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/schachtprofile2022.jpeg?itok=gR8_DEU4&c=6dba7b88948980fbbbcf03bfaa1af0ab)
Aaron Schacht
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/glenn_david.jpg?itok=cw4h5q4U&c=c85d7ae6a8b77de7a553f4c347adc2c2)
Glenn David
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/kathy_turner_2018.jpg?itok=NrEqg8d-&c=41577e72ed6342fc865dd1120652a9d0)
Kathy V. Turner
Ms. Turner has been Corporate Vice President of IDEXX since May 2014 and leads the Company’s Europe, Middle East and Asia (EMEA) Companion Animal Commercial Operations. Prior to joining the Company, from 1987 to May 2014, Ms. Turner held various leadership positions at Abbott Laboratories, Inc., a broad-based healthcare company that manufactures and markets pharmaceuticals, medical products and diagnostics. Most recently, Ms. Turner was Divisional Vice President of European Commercial Operations for the Diagnostics Division from 2011 to 2014, and prior to that, Divisional Vice President of Global Strategic Operations for the Diagnostics Division from 2007 to 2011. Ms. Turner holds a bachelor’s degree in marketing and advertising from Syracuse University.
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/tom_weaver.png?itok=JmhV4S9A&c=f573ac835dc8f61303dbd18d5afb07f3)
Tom Weaver
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/kristin_bloink_headshot_0.jpg?itok=dGE9UJbf&c=e1dd9c4de3eaa5c753dd83788c6eda58)
Kristin Bloink
Kristin Bloink manages all internal discovery efforts and all external technology evaluations and subsequent portfolio entries for R&D. She has 26 years of accomplishments in human clinical trials, animal drug discovery and development, translational model development and execution, and human and veterinary clinical medical delivery in the private as well as the military sector. She joined Novartis Animal Health in 2007 and integrated into Elanco Animal Health in 2015.
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/capture_24.png?itok=1aIqXAqE&c=f90cb0586754b57e02eaab2418450d84)
Fabian Kausche
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/julia_loew_0.jpg?itok=-kMkQRzT&c=1469a91dfe921bb4e875663f09d80bd6)
Julia Loew
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/rebecca_hunt.jpg?itok=8dIMrT0Q&c=42cacb05fa4ffb2efa42edaaf200c45e)
Rebecca Hunt
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/matthias_hofer.jpeg?itok=Zf5dAodU&c=6c01d23134f20517db94e4bbdae1fe5f)
Matthias Hofer
Matthias Hofer is the Managing Partner at Stonehaven Consulting AG with over 15 years of experience in Animal Health. He served on the executive committees of two major Animal Health companies for a total of 7 years. Between 2009 and 2013 he led the global Aqua Health business at Novartis Animal Health (NAH). Later on, he was Global Leader Emerging Business at Elanco and a member of Elanco’s global executive committee. During 2014 and with Elanco’s intention to buy NAH, Matthias served as overall pre-merger integration leader on the Novartis side. In that role, Matthias led a large team and efforts to prepare integration pre-closing overall including carve-out preparations of operations linked to Novartis.
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/matt_dobbs_0.jpg?itok=Wy_0uQrL&c=c3f269c7c5d8fff4ffa99225e5bb521f)
Matt Dobbs
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/apryle_horbal.png?itok=2pIWwrcK&c=0816eea1c25c8dbfbf8e13b2c3c9b67f)
Apryle Horbal
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/peter-mccarthy_headshot.jpg?itok=8Q3VmpEA&c=b438c433388649cf3e9ae80ea1914767)
Peter McCarthy
Mr. McCarthy is now in his 7th year at Henry Schein, Inc. He is currently the Company's President, Global Animal Health Group, as well as a member of Henry Schein's Executive Management Committee.
Mr. McCarthy oversees Henry Schein's animal health business, which spans 24 countries including the United States, Australia, New Zealand, Canada, China, Malaysia, Brazil and 17 countries in Europe.
Before assuming his current position, Mr. McCarthy held key roles at Henry Schein with increasing responsibilities, including President, Henry Schein Animal Health, Europe, and President, Henry Schein Animal Health, International.
Prior to joining Henry Schein, Mr. McCarthy worked at Schering-Plough Animal Health (now Merck Animal Health), serving as Senior Director, Global Operations and General Manager, China. Mr. McCarthy also worked at Wyeth/American Cyanamid for 14 years, helping to grow the human pharmaceutical business.
Mr. McCarthy holds a degree in Applied Biology from the University of Hertfordshire in the U.K., and previously has served as a Member of the Board of the International Federation for Animal Health Europe, and the International Association Executive Animal Health Study Center, CEESA, based in Belgium. Mr. McCarthy is also a graduate and member of the Chartered Institute of Marketing (CIM), which is located in the U.K.
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/rob_polzer.jpg?itok=Mo7Ou-4i&c=65d4392bede531dd985cd2996a4a432a)
Robert Polzer
Partners
Platinum Digital Innovation Partners
Zoetis
Website: www.zoetis.com
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion with approximately 10,600 employees.
For more information, visit www.zoetis.com.
Elanco
Website: www.elanco.com
Elanco Animal Health (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we’re driven by our vision of Food and Companionship Enriching life and our Elanco Healthy Purpose™ CSR framework – all to advance the health of animals, people and the planet.
Gold Digital Innovation Partners
Klifovet
Website: www.klifovet.com
KLIFOVET provides high quality services for the animal health and animal nutrition industry regarding the registration and marketing of all kind of veterinary products. We support ambitious young biotech and veterinary pharma companies on their way to the top by providing full business and product development management, regulatory affairs consultancy including dossier writing, compilation and submission, and full CRO services for safety and efficacy studies. We are proud on 18 years of experience, well organized logistics, a highly motivated team, and a comprehensive net of co-operators and skilled investigators throughout Europe, North America and the world. We handle large multinational projects as professionally as national ones, complying to national, EMA, EFSA or FDA standards.
The Department for International Trade (DIT)
Website: https://www.great.gov.uk/
The Department for International Trade (DIT) helps businesses export and grow into global markets. We also help overseas companies locate and grow in the UK - our services are provided in over 100 markets throughout the world.
We secure UK and global prosperity by promoting and financing international trade and investment, and championing free trade.
We are an international economic department, responsible for:
- bringing together policy, promotion and financial expertise to break down barriers to trade and investment, and help businesses succeed
- delivering a new trade policy framework for the UK as we leave the EU
- promoting British trade and investment across the world
- building the global appetite for British goods and services
Media Partners
IAHJ - International Animal Health Journal
Website: www.animalhealthmedia.com
IAHJ - International Animal Health Journal is a Peer reviewed by our carefully selected editorial advisory panel, and extensive research network, IAHJ reports on Regulations & Validation, Drug Discovery, Development & Delivery, Clinical Research, Nutrition & Infectious Diseases, Custom & Contract Manufacturing, Primary & Secondary Packaging, Logistics & Supply Chain Management, and Marketing & Authorisation of all Drugs, Devices and Food Products that are used in the treatment of animals.
Animal Pharm | IHS Markit
Website: www.animalpharmnews.com
The only source of animal health and animal nutrition news and analysis you’ll ever need.
Animal Pharm gathers intelligence from across the animal health and animal nutrition industries. It keeps you abreast of critical developments, emerging trends, and changes to the business, regulatory and competitive environment.
We have been providing animal health professionals worldwide with news, analysis and insight for over 30 years, and cover the food producing animal and companion animal sectors. With extensive information on animal health products including antiparasitics, vaccines, pharmaceuticals, feed, feed additives and equipment.
Features include:
Analysis of business and company news
Reporting on key players in the industry
Market developments and trends
Analysis of the latest global regulatory changes
News on product research and development
Expert opinion and analysis
The Agenda
Download the full agenda.
Simply fill in this form and we'll send you a PDF version immediately. We need some information to know where to send the file and how to address our email to you.
Download Agenda
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
- Please note that a $70 processing fee will apply to any invoices requested.
- Any questions about your registration, please call +44 (0)20 3696 2920 or email us at [email protected].
- All Prices are in USD
- All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
- No discounts or offers can be combined.
- Please view our Cancellation Policy.
- Emerging Companies are defined as early to mid-stage animal health pharmaceutical or biotech companies that are actively seeking financial investment or product licensing/acquisition. They must be engaged with this company on a full time basis. Those offering consultancy or market intelligence services do not qualify for this rate.
- Please Note: No additional discounts are available on ‘Emerging Company’ pricing.
Global Advisory Board
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/psr.jpg?itok=vrv260vO&c=51e8e622dc34c3afa8d419b23fff6704)
Marc Prikazsky
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/schachtprofile2022.jpeg?itok=gR8_DEU4&c=6dba7b88948980fbbbcf03bfaa1af0ab)
Aaron Schacht
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/huron_sebastien_portrait.jpg?itok=1EkqAONN&c=243909af74d69de6a0d323ca6f165991)
Sébastien Huron
Sébastien Huron, 46, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division. After rejoining the Virbac group in 2006 as the general manager of the Spanish subsidiary, he then became the director of the European region in 2008, and then head of Global Business Operations in 2013. He has been part of the Virbac executive board since December 2012.
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/jean_luc_.jpg?itok=UAovaQ3U&c=d0d66987416cecbca9a549c39149b9ed)
Jean-Luc Michel
After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.
In 2001, Jean-Luc joined Merial, a leader in the animal health industry, where he held some key senior roles, such as EMEA Marketing Director of the Companion Animal Global Enterprise; Head of Marketing EMEA; Executive Marketing Director (Pet Business) in the US; VP, Head of Pet Vet Business Unit; and in 2016 joined the Executive Committee of Merial as Head of Global Commercial Development.
After the acquisition of Merial by Boehringer Ingelheim, Jean-Luc was appointed Head of Global Companion Animal Strategic Business Unit and became a member of the Executive Committee of the Boehringer Ingelheim Animal Health Business Unit.
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/kathy_turner_2018.jpg?itok=NrEqg8d-&c=41577e72ed6342fc865dd1120652a9d0)
Kathy V. Turner
Ms. Turner has been Corporate Vice President of IDEXX since May 2014 and leads the Company’s Europe, Middle East and Asia (EMEA) Companion Animal Commercial Operations. Prior to joining the Company, from 1987 to May 2014, Ms. Turner held various leadership positions at Abbott Laboratories, Inc., a broad-based healthcare company that manufactures and markets pharmaceuticals, medical products and diagnostics. Most recently, Ms. Turner was Divisional Vice President of European Commercial Operations for the Diagnostics Division from 2011 to 2014, and prior to that, Divisional Vice President of Global Strategic Operations for the Diagnostics Division from 2007 to 2011. Ms. Turner holds a bachelor’s degree in marketing and advertising from Syracuse University.
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/261361.jpg?itok=qS3b0YO9&c=12d4ab7bc5a669dfa870a7dde746fa51)
George Gunn
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/linda_rhodes_0.jpg?itok=_omm9e4w&c=133a1a8cb14d07f6f18b91c626c36271)
Linda Rhodes
Dr. Rhodes has over 30 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.
Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has an extensive background in physiology, veterinary medicine, and drug development, and many publications in peer-reviewed journals. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. As a senior research fellow at Merck Research Laboratories for 8 years, she led pre-clinical biology evaluation of several marketed human drugs. She worked for Merial Ltd. as director of large animal development projects, leading project teams developing novel compounds for a variety of indications. In April 2001, she formed AlcheraBio, a consulting, marketing, and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies world-wide. AlcheraBio was acquired in 2008 by Argenta, and Dr. Rhodes served as executive vice president to transition the company when in 2011, she accepted a position as CEO of Aratana Therapeutics, a startup company developing innovative new medicines for dogs and cats. Subsequently, when the company became public she served as its Chief Scientific Officer. During her 5-year tenure, the company achieved FDA approval of three new pet therapeutics: Galliprant, Nocita and Entyce. She is currently retired and an independent consultant. She is a member of the Board of Directors of Zoetis, and serves on the Scientific Advisory Boards of the Alliance for Contraception in Dogs and Cats and the Michelson Found Animals Foundation. She founded Feather in Her Cap, a non-profit that recognizes the achievement of women in the animal health industry. She is the recipient of the Iron Paw Award.
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/alan_1.jpg?itok=p7CD3il6&c=99806fd1b2281b8f389d08acc834a7ca)
Alan Mackay
Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/dave_ross_ceo_agri-epi_centre_headshot.jpg?itok=w8cKwght&c=34e79958b6626a684b5c091d72819952)
Dave Ross
PARTNER WITH US
Based on your objectives, we can create bespoke packages designed specifically for you. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding, and Networking.
Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.